Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program

Dexcom CGM use is proven to improve glycemic control1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring.3

BURNABY, British Columbia--(BUSINESS WIRE)--Mar. 7, 2022-- Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), is pleased to announce that effective March 14 2022, the Ontario government will provide coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program (ADP) for people in the province living with type 1 diabetes who are over 2 years of age and meet coverage criteria.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220307005198/en/

The Dexcom G6 CGM System will be covered through Ontario’s Assistive Devices Program for people living with type 1 diabetes who are over 2 years of age and meet coverage criteria. The back of the upper arm insertion site is for ages 18 and older. (Photo: Business Wire)

The Dexcom G6 CGM System will be covered through Ontario’s Assistive Devices Program for people living with type 1 diabetes who are over 2 years of age and meet coverage criteria. The back of the upper arm insertion site is for ages 18 and older. (Photo: Business Wire)

“We’re pleased to be teaming up with the Ontario government to bring the Dexcom G6 CGM System to more Ontarians living with diabetes. The Dexcom G6 is a life-changing technology for people with diabetes that also brings significant value to the Ontario healthcare system. We are eager to continue this momentum and are committed to working closely with governments across Canada to ensure that every person living with diabetes has access to the care they deserve,” says Laura Endres, Senior Vice President and General Manager of Dexcom Canada.

Ontario joins six other provinces or territories, most recently Alberta, offering public coverage of CGM systems under provincial health plans. The Non-Insured Health Benefits Program also provides coverage for First Nations and Inuit children. With expanded public coverage for CGM, more people can access this standard of care technology, helping them to manage a life-long chronic illness more effectively.4

QUOTES

“Real-time CGM is an essential tool for people managing their diabetes, protection from high and low glucose events leads to more time spent in the target range, allowing people with diabetes to live fuller lives and prevent long term complications. During the pandemic I have moved to almost all virtual visits with my patients. The Dexcom G6 CGM System allows patients to share the trend data of their glucose levels, allowing me to track my patients even when I can’t see them in person and provide personalized care. Access to this technology will be critically important in the wake of COVID 19 as the health care system tries to recover.” — Dr. Ilana Halperin, Endocrinologist, Sunnybrook Health Sciences Centre

“We are pleased with this important step forward. Timely and affordable access to real-time CGM is a priority for JDRF as all people on intensive insulin therapy are entitled to the standard of care that can help them reduce A1C, increase Time in Range, reduce duration and incidence of hypoglycemia and improve quality of life.” — Dave Prowten, President and CEO of JDRF Canada

The Dexcom G6 CGM System includes a small, wearable sensor that measures glucose just below the skin; a transmitter to send glucose levels continuously and wirelessly to a display device; and a compatible smart device* or receiver that displays real-time glucose data to users without the need for calibration or scanning. The Dexcom G6 CGM System provides users with real-time alerts, including a predictive Urgent Low Soon alert that can warn the user in advance of hypoglycemia — giving them time to take appropriate action before it occurs. With the use of the Dexcom Follow App, parents and caregivers can also access their loved one’s glucose levels remotely and be alerted if they are going out of their target glucose range.

In 2021, the Diabetes Canada Clinical Practice Guidelines review committee updated its recommendations for glucose monitoring, stating that real-time CGM (rtCGM), like the Dexcom G6, should be used by individuals with type 1 diabetes treated with basal-bolus insulin injections or an insulin pump in order to reduce A1C and increase time in range, reduce duration and incidence of hypoglycemia and, in adults, improve quality of life.5 The guidelines also state that adults living with type 2 diabetes using basal-bolus and not at target may use rtCGM to reduce A1C and duration of hypoglycemia.6

For more details on how to qualify for ADP coverage, please visit https://www.ontario.ca/page/assistive-devices-program or talk to your doctor or diabetes care team to see if the Dexcom G6 CGM System is the right option for your diabetes management.

About Dexcom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
* For a list of compatible devices, please visit dexcom.com/compatibility
Following requires the Dexcom Follow App and an Internet connection. Followers should always confirm readings on the Dexcom G6 App or Receiver before making diabetes treatment decisions.


1 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.
2 Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2019;21(3):128-32.
3 Roze S, Isitt J, Smith-Palmer J, Lynch P. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor Versus Self-monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. CEOR. 2021;Volume 13:717-725.
4 Cheng AYY, Feig DS, Ho J, et al. Blood glucose monitoring in adults and children with diabetes: update 2021. Canadian Journal of Diabetes. 2021;45(7):580-587.
5 Cheng AYY, Feig DS, Ho J, et al. Blood glucose monitoring in adults and children with diabetes: update 2021. Canadian Journal of Diabetes. 2021;45(7):580-587.
6 Cheng AYY, Feig DS, Ho J, et al. Blood glucose monitoring in adults and children with diabetes: update 2021. Canadian Journal of Diabetes. 2021;45(7):580-587.

Media Contact:
Alena Atkinson, 705.206.9991
Veritas Communications
atkinson@veritasinc.com

Source: Dexcom, Inc.